HK Stock Market Move | LAEKNA-B(02105) rose more than 8% intraday; Phase I SAD study of LAE103 in overweight or obese subjects successfully completed

LAEKNA-B(02105) rose more than 8% intraday, up 6.69% as of press time at HK$6.455, with turnover of HK$1.2681 million. On the news front, on November 9, LAEKNA-B announced that the group has successfully completed the Phase I single ascending dose study (SAD study) of LAE103 (an ActRIIB monoclonal antibody) in overweight or obese subjects in Australia. The SAD study was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic properties of LAE103 (subcutaneous injection) in overweight or obese subjects. Single subcutaneous administration of LAE103 was well tolerated with a good safety profile; no serious adverse events were reported, and there were no reports of dosing discontinuation due to adverse events. The study observed clear target engagement and expected pharmacodynamic biomarker changes. Single-dose LAE103 demonstrated dose-proportional pharmacokinetic characteristics and a clear pharmacokinetic/pharmacodynamic correlation, demonstrating that LAE103 has the therapeutic potential for once-monthly subcutaneous dosing and excellent druggability.